VIYASHNSE20 May 2025

Sequent Scientific Limited has informed the Exchange about Investor Presentation

Viyash Scientific Limited

Download PDF ↗View VIYASH Stock →

Proven Ability In Life Sciences

May 21, 2025

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001

National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Subject: Press Release and Investor Presentation for FY 2024-25

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release and Investor Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully, For Sequent Scientific Limited

Yoshita Vora Company Secretary & Compliance Officer

Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

SeQuent Scientific Limited

Tel No.: +91 9391139986 / 22-4111 4777 I CIN: L99999TS1985PLC196357 Website: http://www.sequent.in I Email Id: investorrelations@sequent.in

SeQuent growth continues to accelerate Q4 FY25 – Revenues at ₹ 4,017 Million up by 11.2%, EBITDA at ₹ 569 Million up 38.7%

FY25 – Revenues at ₹ 15,514 Million up by 13.3%, EBITDA at ₹ 1,993 Million up 86.6% Mumbai, May 20, 2025

SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health Formulations and APIs announced its financial results today for the quarter and year March 31, 2025

Consolidated Financial Highlights

₹ in millions

Q4FY25

Q4FY24

Growth %

FY25

FY24

Growth %

Revenues

EBITDA

Margins

4,017

569

3,612

411

11.2%

38.7%

14.2%

11.4%

280 bps

15,514

1,993

12.8%

13,697

1,068

7.8%

13.3%

86.6%

500 bps

Detailed presentation on the performance forms part of this press release

Commenting on the Company’s performance, Rajaram Narayanan, Managing Director stated “This quarter reinforces the momentum that we have

built in the business over the last 18 months. The significant improvement in profitability metrics and double-digit revenue growth has come on the back

of several initiatives which have helped deliver a superior product mix, accelerate launches and improve operational efficiency. Our proposed merger with

Viyash Life Sciences is proceeding on plan. The strong performance in FY 24-25 marks a turning point for us, as we prepare to accelerate the growth of

the company and create the foundation for the Sequent 3.0 journey.”

Earnings Call with Investors

The Company will conduct an Earnings call at 9:00 AM IST on May 21, 2025 where the Management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are +91 22 6280 1263 or +91 22 7115 8213

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) corporate office in Mumbai, India with a global footprint, operates in the domains of Formulations and APIs. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India’s first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact

Yoshita Vora

Company Secretary, Tel: +91 22 4111 4717

investorrelations@sequent.in

Abhishek Singhal Investor Relations Consultants abhishek@arunya.co.in

Registered Office

3rd Floor, Srivalli’s Corporate,

Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,

Shaikpet, Hyderabad-500033, Telangana

CIN: L99999TS1985PLC196357

BSE Code: 512529 I NSE: SEQUENT

ISIN: INE807F01027 I REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. SeQuent Scientific Ltd. will not be responsible in any way for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstance

INVESTOR PRESENTATION Q4 FY25

S E Q U E N T S C I E N T I F I C L I M I T E D

20th May 2025

Steadfast Commitment to Improvement in Business Fundamentals

“This quarter reinforces the momentum that we have built in the business over the last 18

months. The significant improvement in profitability metrics and double-digit revenue growth

has come on the back of several initiatives which have helped deliver a superior product mix,

accelerate launches and improve operational efficiency. Our proposed merger with Viyash

Life Sciences is proceeding on plan. The strong performance in FY 24-25 marks a turning

point for us, as we prepare to accelerate the growth of the company and create the

foundation for the Sequent 3.0 journey.”

Rajaram Narayanan

Managing Director and CEO

SeQuent & Viyash : Proforma Q4FY25 Combined Performance

Q4 FY25 Performance Highlights (Combined)

Revenues

Adj. EBITDA1

Adj. EBITDA margin

All values in ₹ Mn

Net Debt to LTM Adj. EBITDA1

₹7,725 Million

₹1,222 Million

15.8%

1.0x

13.2% YoY

63.2% YoY

485 bps YoY

vs. 1.2x in Q3FY25

Notes: 1. Viyash EBITDA is adjusted for one-time contractual bonus payable to Viyash management; EBITDA for SeQuent is adjusted for ESOP costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

FY25 Performance Highlights (Combined)

Revenues

Adj. EBITDA1

Adj. EBITDA margin

All values in ₹ Mn

Net Debt to LTM Adj. EBITDA1

₹30,094 Million

₹4,539 Million

15.1%

1.0x

12.3% YoY

65.7% YoY

488 bps YoY

vs. 1.2x in Q3FY25

Notes: 1. Viyash EBITDA is adjusted for ESOP costs, cost for accelerated vesting of warrants, call option charge, merger expenses and one-time contractual bonus payable to Viyash management; EBITDA for SeQuent is adjusted for ESOP Costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

SeQuent : Q4FY25 Performance Update

Strong profitable business growth continues in Q4FY25

All values in ₹ Mn

Revenues

Adj. EBITDA1

Adj. EBITDA margin

PAT

₹4,017 Million

11.2% YoY

₹569 Million

38.7% YoY

14.2%

280 bps YoY

₹103 Million

712% YoY

Note: 1. EBITDA for SeQuent is adjusted for ESOP Costs

FY25: Closed the year with healthy double-digit profitable growth

All values in ₹ Mn

Revenues

Adj. EBITDA1

Adj. EBITDA margin

Net Debt to LTM Adj. EBITDA1

₹15,514 Million

₹1,993 Million

12.8%

1.9x

13.3% YoY

86.6% YoY

505 bps YoY

vs. 3.5x in FY24

Note: 1. EBITDA for SeQuent is adjusted for ESOP Costs

Revenue Performance – by Geography

All values in ₹ Mn

Revenue Distribution

Q4 FY25

Q3 FY25

Q4 FY24

YoY Gr%

FY25

FY24

YoY Gr%

Formulations

Europe

Emerging Markets

India

APIs

Other Sales

Global Sales

One Offs #

3,015

1,323

1,429

263

869

3,008

1,334

1,366

308

812

2,476

1,236

1,007

232

959

3,951

3,843

3,472

22%

42%

13%

(9%)

80%

14%

11,858

5,565

5,138

1,155

3,378

155

9,997

4,868

4,091

1,038

3,260

133

15,392

13,390

(74)

196

307

19%

14%

26%

11%

17%

15%

Adjustment* - Ind AS 29*

Reported Sales

4,017

3,908

140

3,612

11%

15,514

13,697

13%

*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

# Provision for customer claim on shipments in prior years

SeQuent: Q4FY25 Business Performance

All values in ₹ Mn

Europe: Vaccine opportunity proceeding well

Emerging Markets: Resumption of Tablet sales

Formulations

LATAM: Initiated work on the nutraceutical solution range for commercialization

India: Ready for 2nd phase of field expansion to enhance market coverage

Successfully cleared audits by key customers

API

Vizag won Gold – Industrial Safety Excellence Award 2024 by AP FICCI

Mahad awarded by National Safety Council of India – Occupational Health

& Safety Award 2024

1,000+ FDFs

90+ Countries

5 Manufacturing Facilities

35 APIs

50+ Countries

2 Manufacturing facilities

SeQuent: FY25 Business Performance

All values in ₹ Mn

Europe: New product launches & vaccines distribution

Formulations

LATAM: Focus on high margin business, new organisation in Mexico

Emerging Markets: EUGMP renewal, volume recovery and timely price hikes

India: Expanded field team for better coverage

Filed two VMFs during the year, taking the total count at 35

Received WHO Prequalification approval for Albendazole

API

Safety Recognition: Vizag awarded CII Safety Leadership Gold; scored 98.5 (A+) from AP Safety Board

Vizag site received accreditation from JMAFF, Ministry of Agriculture, Forest and Fisheries, Japan

Mahad site recognized for health & occupation safety at National safety council of India

1,000+ FDFs

90+ Countries

5 Manufacturing Facilities

35 APIs

50+ Countries

2 Manufacturing facilities

Consolidated Financials

Particulars

Revenue from Operations Material Consumption Gross Margin % Employee Benefit Expenses Operating Expenses Adj. EBITDA % ESOP cost Exceptional Items IndAS 29 Adjustment* Exchange Gain / (Loss) Other Income Finance Cost Depreciation & Amortization Earnings Before Tax Taxes Earnings After Tax Minority Interest Earnings after Minority Interest

Q4 FY25 4,017 (1,997) 2,020 50.3% (653) (797) 569 14.2% (114) (3) 6 0 16 (151) (161) 163 (59) 103 11 93

Q3 FY25 3,908 (2,025) 1,883 48.2% (651) (738) 494 12.6% (102) (3) 5 (52) 59 (150) (170) 81 (16) 65 30 35

Grw QoQ % 2.8%

7.3%

15.3%

100.6%

59.3%

168.6%

Q4 FY24 3,612 (1,945) 1,667 46.1% (577) (679) 411 11.4% (45) (47) (20) (23) 40 (124) (165) 26 (14) 13 22 (9)

Grw YoY % 11.2%

21.2%

38.7%

517.4%

712.4%

1119%

All values in ₹ Mn

FY25

FY24

15,514 (8,119) 7,395 47.7% (2,487) (2,915) 1,993 12.8% (324) (50) 29 (80) 147 (608) (665) 443 (120) 322 104 219

13,697 (7,597) 6,100 44.5% (2,283) (2,748) 1,068 7.8% (222) (174) (78) (154) 110 (481) (615) (546) 250 (296) 63 (359)

Grw YoY % 13.3%

21.2%

86.6%

181.1%

208.9%

161.0%

Viyash: Business Update

Viyash: Q4FY25 – Continued Strong Performance on Revenue, Profitability and Cashflows

All values in ₹ Mn

Revenues

Adj. EBITDA1

Adj. EBITDA margin

Net Debt to LTM Adj. EBITDA1

₹3,708 Million

15.4% YoY

₹653 Million

93.2% YoY

17.6%

0.3x

710 bps YoY

vs.1.1x In FY24

Notes: 1. Viyash EBITDA is adjusted for one-time contractual bonus payable to Viyash management Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Viyash: FY25 – Robust Full-year Performance

All values in ₹ Mn

Revenues

Adj. EBITDA1

Adj. EBITDA margin

Net Debt to LTM Adj. EBITDA1

₹14,580 Million

₹2,546 Million

17.5%

0.3x

11.2% YoY

52.4% YoY

470 bps YoY

vs.1.1x In FY24

Notes: 1. Viyash EBITDA is adjusted for ESOP costs, cost for accelerated vesting of warrants, call option charge, merger expenses and one-time contractual bonus payable to Viyash management Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Financial Performance

All values in ₹ Mn

Particulars

FY25

FY24

YoY %

FY25

QoQ %

FY25

FY242

YoY %

Revenue from Operations

3,708

3,214

15.4%

3,839

-3.4%

14,580

13,110

11.2%

Material Consumption

(1,652)

(1,420)

16.4%

(1,751)

-5.7%

(6,608)

(6,142)

7.6%

Gross Profit

2,056

1,793

17.1%

2,088

1.5%

7,971

6,968

14.4%

55.4%

55.8%

54.4%

54.7%

53.2%

Operating Expenses

(1,405)

(1,464)

-4.0%

(1,439)

-2.4%

(5,490)

(5,332)

3.0%

Foreign Exchange Gain / (Loss)

Adj. EBITDA1

653

338

93.2%

685

-4.5%

2,546

1,671

52.4%

17.6%

10.5%

17.8%

17.5%

12.7%

Note: 1. EBITDA for Viyash is adjusted for ESOP costs, cost for accelerated vesting of warrants, call option charge, merger expenses and one-time contractual bonus payable to Viyash management 2. Q4 FY24 based on management accounts that have not been subject to limited review by auditors Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Key Updates from Q4FY25

Facility Inspections

3 Regulatory Audits 28 Customer audits

Regulatory Approvals

Launches

6 APIs: USDMF (1), EDMF (3), CN (2)

3 API 1 FDFs

Products Filed

Validations Completed

R&D Pipeline

03 APIs: USDMF (1), CEP (1), EDMF(1)

3 API + 1 intermédiate

25+ Products

Source: Viyash Life Sciences website published Investor Presentation

Viyash: Overview (3 key segments)

APIs

Strategic Innovator & CDMO

Formulations

✓ 70+ commercial products; 23% CAGR for 10 products over FY22-25 with 58% material margins. Market leader for 6 of those products

✓ 200+ customers across 150+ countries; well diversified revenue base with no customer >15% of revenue

✓ 8 plants with strong regulatory & audit track record. Backward integrated portfolio with cost leadership. 35+ audits over the last 10 years from multiple regulators (USFDA, EU GMP, ANVISA, NMPA)

✓ 185+ R&D team; High EHS compliance

(dedicated process safety lab), best in class regulatory & quality teams ✓ Dedicated Oncology facility ✓ Strengthened R&D & BD Team

✓ Existing customer base: 10+ innovators

& complex generic customers

✓ Supplier to top 10 large generic players ✓ Added 10+ development contracts with

innovators and complex generic manufacturers in last 2 years

✓ Portfolio: 23 commercial ANDAs ✓ New Portfolio: 10+ CGTs / NCE-1 / First to File (FTF) products. Focus on complex portfolio

✓ Manufacturing: New Jersey site; local

manufacturing enables US Government & defense business

✓ Integration: All strategic and large volume products under vertical integration for cost leadership

Source: Viyash Life Sciences website published Investor Presentation

Merger Update

Q4FY25: Combined Business Performance

Q4 FY25 (For the quarter)

Revenue (INR Mn)

Adj. EBITDA1 (INR Mn)

Adj. EBITDA Margin %

Net Debt to LTM Adj. EBITDA

SeQuent

Combined

YoY Growth % (Combined)

3,708

4,017

7,725

13.2%

653

569

1,222

63.2%

17.6%

14.2%

15.8%

+485bps

0.3x

1.9x

1.0x

FY25: Combined Business Performance

FY25

Revenue (INR Mn)

Adj. EBITDA1 (INR Mn)

Adj. EBITDA Margin %

SeQuent

Combined

YoY Growth % (Combined)

14,580

15,514

30,094

12.3%

2,546

1,993

4,539

65.7%

17.5%

12.8%

15.1%

+488bps

Net Debt to LTM Adj. EBITDA

0.3x

1.9x

1.0x

Combined P&L – Snapshot

Particulars

Revenue from Operations Material Consumption Gross Margin % Operating Expenses Operating Exchange Gain / (Loss) Adjusted EBITDA % ESOP cost Exceptional Items1 Ind AS 29 Adjustment Exchange Gain / (Loss) Other Income Finance Cost D&A Amortization of Acquisition Intangibles Profit Before Tax Taxes Profit After Tax Adjusted PAT2

Viyash

SeQuent

Combined

FY24 13,110 (6,142) 6,968 53.2% (5,332) 34 1,671 12.7% (127) (58) - - 502 (332) (718) (935) 3 (88) (85) 640

FY25 14,580 (6,608) 7,971 54.7% (5,490) 65 2,546 17.5% (82) (979) - - 182 (256) (720) (1,003) (311) 146 (165) 1,296

FY24 13,697 (7,597) 6,100 44.5% (5,031) - 1,068 7.8% (222) (174) (78) (154) 110 (481) (539) (76) (546) 250 (296) (63)

FY25 15,514 (8,119) 7,395 47.7% (5,402) - 1,993 12.85% (324) (50) 29 (80) 147 (608) (589) (76) 443 -120 322 429

FY24 26,807 (13,739) 13,068 48.7% (10,363) 34 2,739 10.2% (349) (232) (78) (154) 612 (813) (1,257) (1,011) (543) 162 (381) 591

FY25 30,094 (14,727) 15,367 51.1% (10,892) 65 4,539 15.1% (406) (1,029) 29 (80) 329 (864) (1,309) (1,079) 132 26 157 1,725

All values in ₹ Mn

Key Notes :

ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events: - Exceptional Items include cost of

accelerated vesting for share warrants, call option charge, merger expenses and provision for one-time costs

- Amortization of acquisition intangibles in

Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27

Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses and one-time contractual bonus payable to Viyash management PAT adjusted for Amortization of acquisition intangibles (net of tax) and Exceptional Items

1. 2. Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Combined Balance Sheet & Cash Flow: INR 2.5bn in Free Cash Generation in FY25

All values in ₹ Mn

Balance Sheet

Non-Current Assets

Fixed Assets

Goodwill

Other Non-Current Assets

Net Current Assets

Accounts Receivables

Inventories

Accounts Payable

Net Working Capital

Combined

FY24

FY25

23,583

10,592

23,062

10,332

7,569

5,422

5,254

6,604

6,979

4,707

8,876

7,961

4,769

8,071

6,822

4,995

9,898

Other Net Current Assets

(3,622)

(1,826)

Cash Flow

Adj. EBITDA

Less: NWC

Less: Tax

Less: Others

Op. CF

Less: Capex

FCF

Add: Proceeds from Sale of Fixed Assets

Less: Acquisition of Residual Stake in Viyash Subsidiary (Symed)1

Add: Proceeds from Rights Issue (at Viyash)

Equity

Minority Interest

Other Non-Current Liabilities

Net Debt

Debt

Cash

20,364

24,419

1,312

1,144

6,017

7,580

1,563

1,334

700

4,681

6,083

1,403

Borrowings

Less: Interest paid

Add: Proceeds from ESOPs

Others

Cash Generation

1. 26% stake acquired in Symed (100% owned subsidiary post transaction) in July 2024

Combined

FY24

FY25

2,739

4,539

(1,207)

(441)

312

(580)

(479)

1,402

3,548

(1,189)

(1,091)

214

689

2,457

210

(3,907)

3,127

495

(1,473)

(929)

(934)

(1)

(38)

429

286

(160)

Merger – Process Update

Merger process status update

• CCI approval received

• Stock exchange NOC process underway - scheme under review

and final NOC awaited

• Upon receipt of NOC, NCLT filing to be made

• Other regulatory approvals, if any to follow

Expected timelines for the completion of the merger process as indicated to be 12-15 months (from merger announcement in September 2024).

This remains unchanged versus prior quarter as process is well on track as per estimated timelines

Synergy Update

Synergy Planning Process on Track

✓ CCI approval received

✓ Senior management teams have identified & prioritized synergy areas

✓ Integration planning workshops kicked off in Q4FY25

✓ Granular synergy action plan & estimated value to be presented to board in H1FY26

4 Core synergy areas identified

Synergy Realization Timeline (Months)

Area

Key Ideation Action Items

Till Merger Approval

0-6

6-12

12+

R&D

Manufacturing

Sales

• R&D teams to be co-located; to work collaboratively on NPD & cost improvement

• QA & Testing to be moved on- site from 3rd party location

• Utilize available low-cost

capacity through the group; action plan created • Procurement synergies

• Leverage key relationships of both companies; outreach & discussion plan prepared

Others

• Assess shared administrative

& support functions

In advanced stages

We are here

Group Strategy

Key Pillars of our Strategy

Build a unique, differentiated, global end-to-end integrated platform with leadership in animal and global pharmaceuticals

Aspiration

API++

Strategic

Innovator and

CDMO

Global Formulations

Management Team: Senior management team with deep domain experience and global track record

Operating Infrastructure: Global footprint of 15 plants (10 USFDA approved) with a best-in-class Quality & Regulatory teams

Research & Development: Strong R&D, Portfolio and state of the art analytical capabilities, and process safety lab

API++: Key Differentiators

Products

Customers & Markets

Manufacturing

Operating Backbone

200+ products in portfolio across animal & human health care. Basket of high value medium volume products (no product > 13% FY25 API++ Revenue)

Well diversified business with 175+ customers across 150+ markets; top 5 customers accounts for 15% of FY25 Revenue

14+ plants with FDA, EU GMP, ANVISA registrations with 15+ cumulative FDA audits

200+ R&D resources; invested in analytical team, regulatory and IP setup. Highly backward integrated for cost leadership

INR 13.5bn in FY25 Revenue (45% of Combined FY25 Revenue)

% of FY25 API++ Revenue

Market Share (%)1

Markets

13.0%

9.4%

7.1%

6.0%

3.8%

3.6%

3.4%

2.8%

2.4%

56%

61%

27%

47%

50%

59%

50%

38%

35%

29%

60%

46%

USA, Europe, LATAM, RoW

Europe, LATAM, RoW

USA, Europe, LATAM, RoW

Europe, LATAM, ROW

US, Europe, LATAM, ROW

Europe, ROW

USA, Europe, LATAM, RoW

Europe, LATAM, RoW

US, Europe, LATAM, ROW

Product

Product 1

Product 2

Product 3

Product 4

Product 5

Product 6

Product 7

Product 8

Product 9

Product 10

Total

1. Source: IMS MAT

Top 10 products grew at 16% CAGR over FY22-25; 57% Material Margin

API++: Drivers of future growth

Dimension

Current State of Play

Key growth levers

Portfolio

• Filed 31 products & validated 22 products in

FY25

• Developing oncology focused portfolio across all

OEBs

• 35+ products in the pipeline; complex portfolio

Manufacturing

• 220+ cumulative regulatory and customer

audits

• Adding (i) spray drying capabilities in high potent manufacturing & (ii) 300KL+ expanding capacity in 2 sites

R&D

Others

• Dedicated lab set up to handle high potency

Cytotoxic products across all OEBs

• Focusing on development and supply of

• Developed and validated 4 complex Generics CDMO projects for 3+ US, EU and Indian based customers

differentiated/ hard-to-make Generics projects with Global customers on CDMO model

• Management team, manufacturing base and R&D infrastructure built out for next phase of growth

• Operating leverage

Global Formulations: Key Differentiators

Wide Portfolio

Global Markets

Leadership position

Quality Manufacturing

1,000+ SKUs across multiple segments (gut health, pain management, injectables, etc.) and species

300+ field force across 10 core markets

Top 5 market position in focus segments across multiple large markets like Spain ,Brazil & Turkey

6 manufacturing facilities, across multiple capabilities (e.g., manufacturing injectables)

INR 15.7 bn in FY25 Revenue (52% of Combined FY25 Revenue)

Market

% of FY25 Formulations Revenue

Sales Team Count

Europe (Animal Health)

Emerging Markets (Animal Health)

India (Animal Health)

USA (Human Health)

Total

36%

33%

23%

100%

Sales team includes contracted salesforce as well (both exclusive and non-exclusive)

300+

Revenue CAGR of 7% over FY22-25

Global Formulations: Drivers of future growth

Dimension

Current State of Play

Key Growth Levers

Portfolio

Market access

•

1000+ SKUs across multiple species and delivery forms (injectables, orals, supplements)

• Ready-to-market technical materials for geo-extension of

products across markets

• Expand key brands globally • Opportunistic in-licensing and marketing

deals

• Direct presence in 10 countries, 300+ field force • Distributor-led presence in 80+ countries • Repeatable playbook for market entry – portfolio selection, product registrations, commercial investments, technical marketing, local in-licensing

• Market expansion – Scale up India and key markets via investment in Sales team footprint creating a “network effect”

• New markets - Entering new SEA

market; multiple Latam/EU markets open

Segments

• Coverage in Production and select Companion Animal therapies •

Focus on high-growth niches (injectables, pain, gut, supplements)

Innovation and R&D

• •

In-house 35+ member R&D team across global sites 22 product launches in the last 3 years

Team

M&A

• Management team fully built out for next phase of growth

• Proven M&A playbook – 9 M&A over the last 10 years

• Strong right to win to expand into complementary segments like dermatology, ophthalmology, oncology etc.

30+ product strong R&D pipeline • • Culture of Innovation and ideation built

across all levels

• Select additions for next phase of

growth; operating leverage expected

•

Focused M&A to expand products, segments and markets

Sales team includes contracted salesforce as well (both exclusive and non-exclusive)

Strategic Innovator and CDMO business

Acquisitions Acquire capabilities to accelerate growth; Net Debt / Combined Adj. EBITDA <1x

Leverage Relationships Combined business has relationship with multiple Innovators & Complex Generic customers

4 Key Levers to Accelerate Growth

Augment R&D Capabilities Add chemical, process and analytical R&D resources to deliver customer excellence

Invest in Operating Capabilities Created adequate capacity; invested in oncology facilities ahead of scale

To be initiated

In progress

For details, feel free to contact:

Yoshita Vora

Company Secretary

Abhishek Singhal

Investor Relations Consultant

+91 22 4111 4777

abhishek@arunya.co.in

investorrelations@sequent.in

Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39,

Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana

Websites: www.sequent.in, www.alivira.co | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Thank You

← All Transcripts VIYASH Stock Page →

Sequent Scientific Limited has informed the Exchange about Investor Presentation

Market Movers